This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Jan;57(1):106176.

doi: 10.1016/j.ijantimicag.2020.106176.

Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial

Marcelo Rodrigues Dos Santos¹

Affiliations

PMID: 33408022
PMCID: PMC7833570
DOI: 10.1016/j.ijantimicag.2020.106176

Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial

Marcelo Rodrigues Dos Santos. Int J Antimicrob Agents. 2021 Jan.

. 2021 Jan;57(1):106176.

doi: 10.1016/j.ijantimicag.2020.106176.

Author

Marcelo Rodrigues Dos Santos¹

Affiliation

¹ Instituto do Coração do Hospital das Clínicas da Universidade de São Paulo (InCor HC-FMUSP), Brazil. Electronic address: Marcelo.rs@usp.br.

PMID: 33408022
PMCID: PMC7833570
DOI: 10.1016/j.ijantimicag.2020.106176

No abstract available

PubMed Disclaimer

Similar articles

Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Saad MO. Saad MO. Int J Antimicrob Agents. 2021 Jan;57(1):106171. doi: 10.1016/j.ijantimicag.2020.106171. Int J Antimicrob Agents. 2021. PMID: 33408024 Free PMC article. No abstract available.
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Wambier CG. Wambier CG. Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175. Int J Antimicrob Agents. 2021. PMID: 33408021 Free PMC article. No abstract available.
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Parra-Lara LG, Martinez-Arboleda JJ, Isaza-Pierotti DF, Rosso F. Parra-Lara LG, et al. Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172. Int J Antimicrob Agents. 2021. PMID: 33408017 Free PMC article. No abstract available.
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Fiolet T, et al. Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26. Clin Microbiol Infect. 2021. PMID: 32860962 Free PMC article.
Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Hache G, Rolain JM, Gautret P, Deharo JC, Brouqui P, Raoult D, Honoré S. Hache G, et al. Microb Drug Resist. 2021 Mar;27(3):281-290. doi: 10.1089/mdr.2020.0232. Microb Drug Resist. 2021. PMID: 33729874 Free PMC article. Review.

See all similar articles

Cited by

Prophylactic treatment with oral azithromycin in cancer patients during the COVID-19 pandemic (OnCoVID): a randomized, single-blinded, placebo-controlled phase 2 trial.
Mair MJ, Maj-Hes A, Nussbaumer-Pröll A, Puhr R, Christenheit A, Troch M, Puhr HC, Starzer AM, Steindl A, Eberl S, Haslacher H, Perkmann T, Minichsdorfer C, Prager GW, Lamm WW, Berghoff AS, Kiesewetter B, Zeitlinger M, Preusser M, Raderer M. Mair MJ, et al. Infect Agent Cancer. 2023 Feb 12;18(1):9. doi: 10.1186/s13027-023-00487-x. Infect Agent Cancer. 2023. PMID: 36782325 Free PMC article.
Response to advances statistical methods and designs for clinical trials for COVID-19.
Gautret P, Hoang VT, Lagier JC, Raoult D. Gautret P, et al. Int J Antimicrob Agents. 2021 Jan;57(1):106235. doi: 10.1016/j.ijantimicag.2020.106235. Int J Antimicrob Agents. 2021. PMID: 33408028 Free PMC article. No abstract available.
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
Gautret P, Lagier JC, Honoré S, Hoang VT, Colson P, Raoult D. Gautret P, et al. Int J Antimicrob Agents. 2021 Jan;57(1):106243. doi: 10.1016/j.ijantimicag.2020.106243. Int J Antimicrob Agents. 2021. PMID: 33408014 Free PMC article. No abstract available.

References

1. Gautret P., Lagier JC., Parola P., Hoang VT., Meddeb L., Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int. J. Antimicrob Agent. 2020;56(1) - PMC - PubMed
1. Yogasundaram H., Hung W., Paterson I.D., Sergi C., Oudit G.Y. Chloroquine-induced cardiomyopathy: a reversible cause of heart failure. ESC Heart Fail. Jun 2018;5(3):372–375. doi: 10.1002/ehf2.12276. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations